Your institution may have access to this item. Find your institution then sign in to continue.
Title
Deutetrabenazine shows long‐term effectiveness for tardive dyskinesia.
Abstract
Deutetrabenazine, which has been shown to improve symptoms of tardive dyskinesia (TD) in two 12‐week trials, now has demonstrated longer‐term efficacy and safety. The latest results were found in open‐label extensions of the Aim to Reduce Movements in Tardive Dyskinesia (ARM‐TD) and Addressing Involuntary Movements in Tardive Dyskinesia (AIM‐TD) trials.